(R)-MG-132

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

(R)-MG-132 是 MG-132 的对映体。 (R)-MG-132 立体异构体是比 MG-132 更有效的蛋白酶体抑制剂。 (R)-MG-132 作为一种潜在的胰凝乳蛋白酶样抑制剂、胰蛋白酶样和蛋白酶体肽基谷氨酰肽水解活性进行了研究。

(R)-MG-132 is the enantiomer of MG-132. (R)-MG-132 stereoisomer is a more potent proteasome inhibitor than MG-132. (R)-MG-132 is studied as a potential chymotrypsin-like inhibitor, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities of proteasome. MG-132 and (R)-MG-132 are investigated for inhibition of ChTL, trypsin-like (TL) and peptidylglutamyl peptide hydrolyzing (PGPH) activities of purified 20S proteasomes isolated from human erythrocytes.For (R)-MG-132, the IC50s of 0.22 μM, 34.4 μM, and 2.95 μM for ChTL, TL, and PGPH, respectively. For MG-132, the IC50s of 0.89 μM, 104.43 μM, and 5.7 μM for ChTL, TL, and PGPH, respectively.

(R)-MG-132, the stereoisomer of MG-132, is studied as a potential inhibitor of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities of proteasome.MG-132 and (R)-MG-132 are investigated for inhibition of ChTL, trypsin-like (TL) and peptidylglutamyl peptide hydrolyzing (PGPH) activities of purified 20S proteasomes isolated from human erythrocytes. For MG-132, the IC50s of 0.89 μM, 104.43 μM, and 5.7 μM for ChTL, TL, and PGPH, respectively. For (R)-MG-132, the IC50s of 0.22 μM, 34.4 μM, and 2.95 μM for ChTL, TL, and PGPH, respectively.

——

(S,R,S)-(-)-MG-132,Z-Leu-D-leu-leu-al

Proteasome/Ubiquitin

Proteasome

Proteasome

——

——

1211877-36-9

475.62

C26H41N3O5

>98% (HPLC)

DMSO:100 mg/mL (210.25 mM)

CC(C)C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O

——

(-20℃)

With Ice Pack

≥ 2 years